Non-Interventional Study to Assess the Clinical Outcome in Patients Treated for Poorly Differentiated (High-Grade, G3) Neuroendocrine Carcinomas Except Primary Lung Cancer

Non-Interventional Study to Assess the Clinical Outcome in Patients Treated for Poorly Differentiated (High-Grade, G3) Neuroendocrine Carcinomas Except Primary Lung Cancer - OSHO #087

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005433

Enrollment

Registered

2013-11-12

Start date

2014-05-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poorly differentiated (G3) neuroendocrine carcinomas except primary lung cancer C75.9

Interventions

Group 1: Registry for deidentified documentation of clinical data (stage, histology, tumor site, first-line treatment, second-line treatment, side effects)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with poorly differentiated (G3) neuroendocrine carcinoma except primary lung cancer

Exclusion criteria

Exclusion criteria: primary lung cancer G3

Design outcomes

Primary

Measure	Time frame
Overall survival after first diagnosis	—

Secondary

Measure	Time frame
Response to primary and salvage treatment regimens; progression-free survival, treatment-related adverse events	—

Countries

Germany

Contacts

Public ContactSandra Otto

Universitätsklinikum Leipzig, Abteilung für Hämatologie und internistische Onkologie

0341-97-13132

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026